

REMARKS

The claims pending in the above-identified application following entry of the foregoing amendments will be claims 11-27. Original claims 1-10 have been cancelled.

Claims directed to ophthalmic compositions containing moxifloxacin have been allowed in parent application Serial No. 10/200,868. The new claims submitted above are directed to the use of moxifloxacin to treat ophthalmic infections. As utilized in these claims, the term "treating" is intended to have its common, ordinary meaning, which includes both active and prophylactic treatment of a disease or disorder [see Dorland's Illustrated Medical Dictionary, Twenty-sixth Edition, pages 1388 and 1389 (1981); copy attached].

Respectfully submitted,
ALCON RESEARCH, LTD.

November 17, 2003
Date

By: Gregg C. Brown
Gregg C. Brown
Registration No. 30,613
Phone No. (817) 551-8663

Address for Correspondence:
Gregg C. Brown
Alcon Research, Ltd.
6201 South Freeway, Mail Code Q-148
Fort Worth, Texas 76134-2099
Phone: (817) 551-8663

Attorney Docket No.: 1732 US F2